SequelSEC

Coya Therapeutics, Inc. COYA

Pharmaceutical Preparations · CIK 0001835022 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$243.74K
Fiscal year ended 2026-06-30
Operating income
-$7.05M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$89.42MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$3.81Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue11.3×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity2.1×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Revenue YoY growth123.6%85th
Current ratio8.50x75th
SBC / revenue54.0%62th
Net margin-267.1%45th
Operating margin-283.9%47th

Coya Therapeutics, Inc. (COYA) reported revenue of $243.74K and net income of -$6.64M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Coya Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Coya Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$243.74K$251.15K$3.96M$3.56M$163.62K$257.88K$1.95K$0$3.43M$126.84K
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$7.05M-$7.64M-$6.03M-$2.43M-$6.41M-$7.68M-$4.08M-$4.45M-$3.24M-$5.48M
Net income-$6.64M-$7.21M-$5.71M-$2.12M-$6.09M-$7.31M-$2.92M-$4.02M-$2.89M-$5.05M
Research & developmentUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesshares 23.46Mshares 22.64MUnavailableshares 16.73Mshares 16.72Mshares 16.72MUnavailableshares 15.22Mshares 14.92Mshares 14.46M
Pretax income-$6.64M-$7.21MUnavailableUnavailable-$6.09M-$7.31MUnavailableUnavailable-$2.89M-$5.05M
Income tax expenseUnavailableUnavailableUnavailableUnavailable$0UnavailableUnavailableUnavailable$0Unavailable
Diluted EPS$-0.28$-0.32Unavailable$-0.13$-0.36$-0.44Unavailable$-0.26$-0.19$-0.35
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$2.26M$3.78M$3.27M$2.56M$2.91M$2.71M$2.14M$2.22M$2.09M$2.44M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Coya Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$43.18M$50.72M$46.82M$28.13M$29.76M$35.53M$38.34M$31.06M$36.58M$35.99M
Total assets$47.31M$53.27M$49.95M$32.04M$33.45M$38.40M$44.35M$35.55M$39.94M$37.39M
Current assets$47.06M$53.26M$49.94M$32.02M$33.43M$38.37M$44.31M$35.51M$39.89M$37.33M
Total liabilities$4.03M$4.30M$6.92M$4.76M$5.14M$5.04M$4.77M$3.54M$4.68M$5.00M
Current liabilities$3.51M$3.55M$5.87M$3.67M$4.50M$4.34M$3.82M$2.32M$3.83M$4.32M
Total equity incl. NCI$43.28M$48.97M$43.03M$27.28M$28.31M$33.37M$39.58M$32.01M$35.26M$32.39M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$1.09M$948.19K$1.06M$1.11M$931.34K$1.69M$1.59M$336.72K$1.88M$1.59M

Cash flow

Coya Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$7.38M-$6.21M-$1.01M-$1.13M-$5.77M-$2.83M-$2.41M-$5.46M-$4.56M$2.15M
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flow-$1.66K-$885.00K-$648.61KUnavailableUnavailableUnavailable$0$0$0-$25.00K
Financing cash flow-$166.07K$11.00M$20.35M$19.14K$0$19.14K$9.69M-$56.33K$5.15M$1.24M
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Stock-based compensation$943.91K$2.20M$1.10M$1.07M$1.04M$1.08M$790.55K$775.01K$662.32K$435.66K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Coya Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-2891.1%-3042.1%-152.3%-68.3%-3920.5%-2976.9%-209031.5%Unavailable-94.5%-4322.8%
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenue387.3%874.2%27.9%30.0%633.0%418.8%40499.4%Unavailable19.3%343.5%
Current ratio13.40x15.02x8.50x8.73x7.43x8.84x11.59x15.31x10.43x8.64x
Revenue YoY growth49.0%-2.6%202768.8%Unavailable-95.2%103.3%-100.0%UnavailableUnavailableUnavailable
Net margin-2723.4%Unavailable-144.2%-59.4%-3725.2%Unavailable-149373.8%UnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open COYA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-16View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.